Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efavirenz + tenofovir disoproxil fumarate
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Efavirenz + tenofovir disoproxil fumarate is an oral fixed-dose combination of two antiretroviral drugs used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. **Efavirenz** is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly and non-competitively to reverse transcriptase, disrupting its activity. **Tenofovir disoproxil fumarate (TDF)** is a prodrug of tenofovir, a nucleotide reverse transcriptase inhibitor (NRTI) that inhibits the HIV reverse transcriptase by competing with natural substrates and causing chain termination after incorporation into viral DNA. The combination is designed for use as part of highly active antiretroviral therapy (HAART) regimens, typically in adults and pediatric patients weighing at least 40 kg, to suppress viral replication and decrease the risk of progression to acquired immunodeficiency syndrome (AIDS). These agents do not cure HIV but reduce viral load and transmission risk[2][5][6].
- Brand names
- Atripla
- Other names
- efavirenz + tenofovir disoproxil fumarate
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on efavirenz + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efavirenz + tenofovir disoproxil fumarate.